Novartis Afinitor cancer treatment gets EU approval

As reported by Pharma times, Novartis’s Afinitor has now been approved in Europe as a treatment for advanced breast cancer.

The European Commission has approved Afinitor (everolimus) for use in combination with Pfizer’s Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer

Herve Hoppenot, Novartis Oncology president, said the approval of Afinitor is “an important milestone marking the first major advance for women in the European Union with hormone receptor-positive advanced breast cancer since the introduction of aromatase inhibitors more than 15 years ago!”

This could mean that by boosting the effectiveness of endocrine therapy, Afinitor significantly extends the time women with hormone receptor-positive advanced breast cancer live without tumour progression.

Click here to see our latest clinical roles in the UK and Europe

Posted in: Industry News, News
CK Logo in place of featured image